Piotr Stasiak

7PUBLICATIONS
17CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jul 15, 2026
Vismodegib Exerts a Pleotropic Effect on Topotecan-Resistant and Sensitive Ovarian Cancer Cell Lines in 2D and 3D Cell Culture Models.

|Dec 30, 2025
Elacridar Reverses P-gp-Mediated Drug Resistance in Ovarian Cancer Cells in 2D and 3D Culture Models.

Piotr Stasiak, Justyna Sopel, Julia Maria Lipowicz

|Jun 26, 2025
Elacridar Inhibits BCRP Protein Activity in 2D and 3D Cell Culture Models of Ovarian Cancer and Re-Sensitizes Cells to Cytotoxic Drugs.

Piotr Stasiak, Justyna Sopel, Artur Płóciennik

|Feb 13, 2025
The Role of Elacridar, a P-gp Inhibitor, in the Re-Sensitization of PAC-Resistant Ovarian Cancer Cell Lines to Cytotoxic Drugs in 2D and 3D Cell Culture Models.

Piotr Stasiak, Justyna Sopel, Julia Maria Lipowicz

|Oct 16, 2024
Clinical Aspects and Significance of β-Chemokines, γ-Chemokines, and δ-Chemokines in Molecular Cancer Processes in Acute Myeloid Leukemia (AML) and Myelodysplastic Neoplasms (MDS).

Jan Korbecki, Mateusz Bosiacki, Piotr Stasiak

|Dec 11, 2022
cAMP-Dependent Signaling and Ovarian Cancer.

Agnieszka Kilanowska, Agnieszka Ziółkowska, Piotr Stasiak

Pageof 2

Frequent Collaborators

5 joint publications

Radosław Januchowski

5 joint publications

Jan Korbecki

4 joint publications

Agnieszka Anna Rawłuszko-Wieczorek

3 joint publications

Karolina Sterzyńska